Sanofi’s Dupixent improves symptoms in rhinosinusitis with nasal polyps at Phase 3
New data has been released on Sanofi’s Dupixent (dupilumab), derived from two Phase 3 trials, illustrating the drug’s efficacy In combination with standard of care corticosteroid nasal spray in the treatment of recurring severe chronic rhinosinusitis with nasal polyps (CRSwNP) in patients who have not responded adequately treatment with surgery and/or systemic corticosteroids.
A chronic disease caused by Type 2 inflammation of the upper airway, CRSwNP patients live with polyps which can block the sinuses and nasal passages, leading to difficulties with breathing, facial pain or pressure, subdued sense of smell or taste, nasal discharge, and impaired quality of life.
The data showed that Dupixent plus corticosteroid nasal spray improved nasal polyp size, severity of nasal congestion, chronic sinus disease, sense of smell and co-morbid asthma outcomes. In severe patients, the combo reduced the need for systemic corticosteroid use or nasal/sinus surgery.
Dupixent works by inhibiting interleukin-4 and -13, two proteins considered crucial in Type 2 inflammation, as supported by these latest studies as well as previous studies into atopic dermatitis and asthma.
“Dupixent is the first biologic therapy to demonstrate the potential to produce disease-modifying effects in severe CRSwNP, significantly improving all disease measures in the study, including sense of smell, one of the most troublesome and challenging-to-treat symptoms for patients,” said Dr Claus Bachert, Professor and Head of Clinics of the Department of Otorhinolaryngology at Ghent University and principal investigator of the trials. “Patients with co-morbid CRSwNP and asthma are often more difficult to treat so it is encouraging that Dupixent, which targets key drivers of Type 2 inflammation, may address both conditions in these patients.”
Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a …
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …